For over a decade, pharma and biotech companies as well as academic centers and researchers in Switzerland have been at the forefront of nuclear medicine. As the field of radiopharmaceuticals continues to grow, we discuss how Switzerland can continue to lead and how to enable its full potential in this next era of innovation for cancer patients. Join us !
Tuesday, May 5, 14:00 - 14:45, room Shanghai 3+4
| Name | Position | Institution |
|---|---|---|
| Philippe Girard | Deputy Executive Director | Swissmedic |
| Name | Position | Institution |
|---|---|---|
| Philippe Legenne | CMO | Molecular Partners |
| Andrew Cavey | CEO | ITM Radiopharma |
| Leila Jaafar | CEO | Nuclidium |
| John Prior | Professor and Head of Nuclear Medicine and Molecular Imaging | CHUV |
Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering a novel class of protein drugs known as DARPin therapeutics, for medical challenges other treatment modalities cannot readily address. MP develops targeted radiopharmaceuticals, including MP0712 - a DLL3-targeting lead212-based Radio-DARPin candidate for SCLC in ongoing US Phase 1/2a study, and next-generation immune cell engagers for cancer patients. Founded in 2004, MP has offices in Zurich, Switzerland and Concord, MA, USA.
